Having trouble viewing this email? View in your browser.

We hope our expert panel discussion provided
a clear perspective on how and when to use
antivirals to optimally treat patients with COVID-19.

Your feedback is important to us. Please click here or
scan the QR code for a short survey to let us know how we did.

Click to watch the Gilead symposium on-demand.
The recording will be available for 3 months post-conference.

During this session we:

Adverse events should be reported to Gilead safety and to your national reporting system
This promotional meeting is organised and fully funded by Gilead Sciences Europe Ltd.
Date of preparation: June 2021 IHQ-RDV-0125
Gilead medicines and off-label treatments are discussed
Gilead Sciences does not endorse the off-label usage of medical products
Please refer to the SmPC of any medicinal product prior to prescription


You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.